All In Biotech

Drug Trial Radar · NCT00500656

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)

Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE)

Last checked: Nov 20, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

85

Actual

Start

Mar 1, 2005

Primary completion

Jul 25, 2006

Study completion Jul 25, 2006

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Jul 13, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Outcome Measures: The primary endpoint was the time to onset of symptom relief of the first attack in the double blind phase. H0: λ icatibant/λ tranexamic acid =1 versus H1: λ icatibant/λ tranexamic acid ≠1 Where: λ icatibant refers to the hazard rate under icatibant and λ tranexamic acid refers to the hazard rate under tranexamic acid. Secondary Outcome Measures: * Additional efficacy assessments (Time to Almost Complete Symptom Relief) * Safety and tolerability * Pharmacoeconomics

Conditions

  • Hereditary Angioedema

Interventions

  • IcatibantDrug

    Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.

  • Tranexamic AcidDrug

    over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.

  • Oral PlaceboDrug

    hard capsule matched to tranexamic acid

  • S.C. PlaceboDrug

    solution for injection, matched to icatibant for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Onset of Symptom Relief.Time frame: 2 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Università degli Studi di Milano, Dipartimento di Medicina Interna

    Milan, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.